Best Medical Stocks To Buy For 2019

tags:CNO,APRI,LXFT,BCPC,BNCL,

By: Lars Moffatt

Introduction

The Canadian cannabis market has exploded in value in the last year due to the upcoming legalization of marijuana that is expected to become law in Canada in July of 2018. Within this market, several large corporations are acquiring smaller production companies to increase their market share and prepare for the demand that will occur due to legalization.

Today��s North Channel Investment article will look at Aurora Cannabis Inc. (OTCQX:ACBFF), and why they could be very appealing to any investor looking for a stock that has great potential for long-term growth.

Company Overview

Aurora Cannabis is a Canadian medical marijuana producer that is based out of Vancouver, British Columbia, Canada. The company specializes in the production and distribution of cannabis and cannabis oil. Aurora sells and distributes to patients who are legally entitled to medical cannabis in Canada, where the company offers secure delivery services. These services can be accessed by phone, online, and the company��s innovative mobile application. There are numerous emerging cannabis sellers and producers across North America, however, Aurora is one of Canada��s largest and fastest growing sellers of cannabis and oils. The company owns several subsidiaries that are located in Canada, United States, Germany and Australia. Some of the names of these subsidiaries are as follows:

Best Medical Stocks To Buy For 2019: CNO Financial Group, Inc.(CNO)

Advisors' Opinion:

• [By Stephan Byrd]

  CNO Financial Group (NYSE:CNO) hit a new 52-week high and low during mid-day trading on Tuesday . The company traded as low as $19.32 and last traded at $19.49, with a volume of 149704 shares traded. The stock had previously closed at $19.81.

• [By Shane Hupp]

  Coin(O) (CURRENCY:CNO) traded flat against the U.S. dollar during the twenty-four hour period ending at 21:00 PM ET on May 12th. One Coin(O) coin can now be purchased for about $0.0021 or 0.00000025 BTC on popular exchanges. Coin(O) has a market cap of $222,284.00 and $40.00 worth of Coin(O) was traded on exchanges in the last 24 hours. Over the last seven days, Coin(O) has traded 21.2% lower against the U.S. dollar.

• [By Joseph Griffin]

  CNO Financial Group (NYSE:CNO) announced a quarterly dividend on Thursday, May 10th, Wall Street Journal reports. Stockholders of record on Monday, June 11th will be given a dividend of 0.10 per share by the financial services provider on Monday, June 25th. This represents a $0.40 annualized dividend and a dividend yield of 1.96%. The ex-dividend date of this dividend is Friday, June 8th. This is a boost from CNO Financial Group’s previous quarterly dividend of $0.09.

Best Medical Stocks To Buy For 2019: Apricus Biosciences, Inc(APRI)

Advisors' Opinion:

• [By Chris Lange]

  Apricus Biosciences Inc. (NASDAQ: APRI) has a PDUFA goal date for completion of the FDA��s review of the Vitaros NDA set on February 17. Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction (ED) and a new potential entrant into the U.S. ED treatment market. So far Vitaros has been approved in Canada, Mexico and certain countries in Europe, Latin America and the Middle East. Shares of Apricus were last seen at $2.22, with a 52-week range of $0.86 to $3.49 and a consensus price target of $3.50.

• [By Paul Ausick]

  Apricus Biosciences Inc. (NASDAQ: APRI) also dropped about 38% Monday to post a new 52-week low of $0.26. Shares closed at $0.42 on Friday and the stock’s 52-week high is $3.34. Volume was more than three times the daily average of around 1.4 million shares. The company is considering its options after the U.S. FDA directed the firm to develop a new formulation for its erectile dysfunction drug, Vitaros.

• [By William Romov]

  California-based Apricus Biosciences Inc. (Nasdaq: APRI) develops treatments in the areas of urology and rheumatology. Its lead product, Vitaros, is a topically applied cream for the treatment of erectile dysfunction (ED).

Best Medical Stocks To Buy For 2019: Luxoft Holding, Inc.(LXFT)

Advisors' Opinion:

• [By Logan Wallace]

  Luxoft (NYSE: LXFT) and Zscaler (NASDAQ:ZS) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

• [By Lisa Levin]

  Luxoft Holding, Inc. (NYSE: LXFT) was down, falling around 26 percent to $32.15. Luxoft posted in-line Q4 earnings, but issued weak forecast for the current quarter.

• [By Shane Hupp]

  Luxoft Holding Inc (NYSE:LXFT) has been given an average rating of “Hold” by the fourteen brokerages that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, six have given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $53.33.

• [By Motley Fool Staff]

  Luxoft Holding (NYSE:LXFT) Q4 2018 Earnings Conference CallMay. 24, 2018 8:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Steve Symington]

  Shares of Luxoft Holding Inc. (NYSE:LXFT) were down 21.3% as of 11:30 a.m. EDT Thursday after the software development company announced strong quarterly results, but followed with light guidance.

Best Medical Stocks To Buy For 2019: Balchem Corporation(BCPC)

Advisors' Opinion:

• [By Stephan Byrd]

  Balchem Co. (NASDAQ:BCPC) shares reached a new 52-week high and low on Wednesday . The stock traded as low as $96.61 and last traded at $96.33, with a volume of 2460 shares traded. The stock had previously closed at $95.08.

• [By Logan Wallace]

  JPMorgan Chase & Co. boosted its position in shares of Balchem Co. (NASDAQ:BCPC) by 20.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,196 shares of the basic materials company’s stock after buying an additional 12,487 shares during the period. JPMorgan Chase & Co.’s holdings in Balchem were worth $5,985,000 at the end of the most recent quarter.

• [By Logan Wallace]

  Shares of Balchem Co. (NASDAQ:BCPC) hit a new 52-week high and low on Monday . The company traded as low as $97.20 and last traded at $96.87, with a volume of 107919 shares. The stock had previously closed at $96.52.

• [By Travis Hoium]

  Nearly every business Balchem�(NASDAQ:BCPC) is in has seen strong growth in 2018, and that's driving the company's financial results higher. Fracking is seeing the biggest growth, but human and animal health continue to be great businesses for the company.�

• [By Max Byerly]

  Carillon Tower Advisers Inc. boosted its stake in Balchem Co. (NASDAQ:BCPC) by 656.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 55,180 shares of the basic materials company’s stock after purchasing an additional 47,884 shares during the period. Carillon Tower Advisers Inc. owned about 0.17% of Balchem worth $4,510,000 at the end of the most recent reporting period.

Best Medical Stocks To Buy For 2019: Beneficial Mutual Bancorp Inc.(BNCL)

Advisors' Opinion:

• [By Joseph Griffin]

  Media coverage about Beneficial Bancorp (NASDAQ:BNCL) has trended positive recently, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Beneficial Bancorp earned a news impact score of 0.38 on Accern’s scale. Accern also gave media headlines about the bank an impact score of 45.8699493506664 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

• [By Ethan Ryder]

  BidaskClub upgraded shares of Beneficial Bancorp (NASDAQ:BNCL) from a sell rating to a hold rating in a report released on Tuesday morning.

  Shares of Beneficial Bancorp opened at $16.35 on Tuesday, MarketBeat.com reports. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $1.23 billion, a P/E ratio of 31.44 and a beta of 0.55. Beneficial Bancorp has a fifty-two week low of $14.40 and a fifty-two week high of $17.50.

• [By Logan Wallace]

  Beneficial Bancorp (NASDAQ: BNCL) and Home Bancorp (NASDAQ:HBCP) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

• [By Joseph Griffin]

  Beneficial Bancorp Inc (NASDAQ:BNCL) Director Thomas J. Lewis sold 973 shares of the company’s stock in a transaction dated Wednesday, May 30th. The stock was sold at an average price of $16.50, for a total value of $16,054.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.